Morgan Stanley
PYXS icon

Morgan Stanley’s Pyxis Oncology PYXS Stock Holding History

Morgan Stanley’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Sell
33,448
-36,240
-52% -$69.3K ﹤0.01% 6251
2026
Q1 		$102K Sell
69,688
-19,534
-22% -$29.4K ﹤0.01% 6154
2025
Q4 		$103K Sell
89,222
-17,385
-16% -$61.3K ﹤0.01% 6186
2025
Q3 		$237K Sell
106,607
-53,567
-33% -$77.2K ﹤0.01% 5825
2025
Q2 		$176K Sell
160,174
-286,308
-64% -$323K ﹤0.01% 5904
2025
Q1 		$438K Buy
446,482
+203,751
+84% +$272K ﹤0.01% 5389
2024
Q4 		$379K Buy
242,731
+89,483
+58% +$258K ﹤0.01% 5540
2024
Q3 		$562K Buy
153,248
+70,637
+86% +$247K ﹤0.01% 5346
2024
Q2 		$273K Buy
82,611
+39,084
+90% +$164K ﹤0.01% 5543
2024
Q1 		$185K Buy
43,527
+40,327
+1,260% +$170K ﹤0.01% 5762
2023
Q4 		$5.76K Hold
3,200
– – ﹤0.01% 6801
2023
Q3 		$6.37K Buy
3,200
+2,700
+540% +$6.26K ﹤0.01% 6858
2023
Q2 		$1.28K Sell
500
-168,076
-100% -$533K ﹤0.01% 7262
2023
Q1 		$676K Buy
168,576
+62,157
+58% +$124K ﹤0.01% 5080
2022
Q4 		$143K Sell
106,419
-15,581
-13% -$23.4K ﹤0.01% 5812
2022
Q3 		$240K Sell
122,000
-14,877
-11% -$38.9K ﹤0.01% 5642
2022
Q2 		$325K Buy
136,877
+133,691
+4,196% +$356K ﹤0.01% 5640
2022
Q1 		$12K Buy
3,186
+354
+13% +$2.59K ﹤0.01% 7353
2021
Q4 		$31K Buy
+2,832
New +$32.4K ﹤0.01% 7029

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's PYXS Position: Q2 2026 in Review

Morgan Stanley reduced its Pyxis Oncology (PYXS) stake by 52% in Q2 2026, selling an estimated $69.3K and leaving 33,448 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #6251.

Morgan Stanley first reported a position in PYXS in Q4 2021 and has held it in 19 quarters since. The position peaked at $676K in Q1 2023. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Morgan Stanley held 33,448 shares of Pyxis Oncology worth $101K as of Q2 2026.
  • Morgan Stanley sold 36,240 Pyxis Oncology shares in Q2 2026, an estimated $69.3K.
  • Pyxis Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6251 holding.
  • Morgan Stanley first reported a position in Pyxis Oncology in Q4 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Pyxis Oncology position peaked at $676K in Q1 2023.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.